Bristol Myers Squibb

DGAP-News: EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE

Tuesday, May 11, 2021 - 7:00am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.

Innate Pharma First Quarter 2021 Report

Tuesday, May 11, 2021 - 6:00am

This cohort reached the pre-determined number of responses needed to advance to stage 2 earlier than anticipated.

Key Points: 
  • This cohort reached the pre-determined number of responses needed to advance to stage 2 earlier than anticipated.
  • More information on this study can be found at clinical trials.gov .\nCash, cash equivalents and financial assets of the Company amounted to \xe2\x82\xac181.7 million as of March 31, 2021.
  • At the same date, financial liabilities amounted to \xe2\x82\xac18.5 million.\nDuring the first quarter of the year 2021, a \xe2\x82\xac7.0m milestone payment was received from Sanofi in February 2021.
  • This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.\nHeadquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\nLearn more about Innate Pharma at: www.innate-pharma.com\nInformation about Innate Pharma shares:\n'

Global HIV Drugs Market Report 2021: Long-term Forecast to 2025 & 2030 - ResearchAndMarkets.com

Friday, May 7, 2021 - 6:23pm

b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.

Key Points: 
  • b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.
  • HIV drugs are repurposed to treat Covid 19 infections.
  • Global HIV Drugs Historic Market, 2015-2020, $ Billion\n5.2.
  • Global HIV Drugs Forecast Market, 2020-2025F, 2030F, $ Billion\n'

CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

Thursday, May 6, 2021 - 9:15pm

This combination is also being evaluated by Bristol Myers Squibb in a randomized study in patients with metastatic melanoma.

Key Points: 
  • This combination is also being evaluated by Bristol Myers Squibb in a randomized study in patients with metastatic melanoma.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody\xc2\xae technology platform, for the treatment of cancer.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .\nThis press release includes forward-looking statements.
  • CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.\nProbody is a U.S. registered trademark of CytomX Therapeutics, Inc.\n'

DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative

Thursday, May 6, 2021 - 1:14pm

b'NEW YORK, May 6, 2021 /PRNewswire/ --DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).

Key Points: 
  • b'NEW YORK, May 6, 2021 /PRNewswire/ --DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).
  • The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.\nThe methodology underpinning the NCTI is based on an understanding of critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations.
  • "Once identified and prioritized, these targets can undergo rigorous experimental validation to drive drug development for a new generation of anti-cancer therapies that could be developed by Bristol Myers Squibb.
  • "\nDarwinHealth\'s mission statement is to deploy novel technologies rooted in systems biology to improve clinical outcomes of cancer treatment.

DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative

Thursday, May 6, 2021 - 1:03pm

b'NEW YORK, May 6, 2021 /PRNewswire/ --DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).

Key Points: 
  • b'NEW YORK, May 6, 2021 /PRNewswire/ --DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).
  • The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.\nThe methodology underpinning the NCTI is based on an understanding of critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations.
  • "Once identified and prioritized, these targets can undergo rigorous experimental validation to drive drug development for a new generation of anti-cancer therapies that could be developed by Bristol Myers Squibb.
  • "\nDarwinHealth\'s mission statement is to deploy novel technologies rooted in systems biology to improve clinical outcomes of cancer treatment.

DGAP-News: Evotec launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

Thursday, May 6, 2021 - 7:00am

"\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.

Key Points: 
  • "\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.
  • With beLAB1407, we are supporting U.K.-based universities that are exploring many interesting lines of scientific research and discovery.
  • That research combined with Evotec\'s proprietary data platforms has the potential to identify new and novel therapies for areas of unmet medical need.
  • "\nDr George Baxter, Chief Executive of Edinburgh Innovations, said: "This innovative collaboration represents the best of academic and industry collaboration.

Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Wednesday, May 5, 2021 - 11:59am

b'Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021.

Key Points: 
  • b'Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021.
  • Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer will answer questions about the company at 5 p.m. ET.\nInvestors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com .
  • An archived edition of the session will be available later that day.\nBristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .\n'

NJ Bio Moves Headquarters to Princeton, New Jersey

Tuesday, May 4, 2021 - 5:03pm

View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .
  • NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.\n\xe2\x80\x9cOn behalf of the board of directors and senior management at NJ Bio, I am excited to announce this move,\xe2\x80\x9d said Nareshkumar Jain , Ph.D., President and CEO of NJ Bio.
  • \xe2\x80\x9cOur expansion to this advanced facility demonstrates the rapid growth of NJ Bio in just over two years.
  • NJ Bio also offers expertise in flow chemistry and process development and provides innovative solutions for large-scale continuous manufacturing needs.

DGAP-News: Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Tuesday, May 4, 2021 - 11:28am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.